Table 3.

Timeline changes in cytokeratin + cells in patients’ PBMCs

In vitro Treatment	Cytokeratin %	EpCam %	Oct4%	Tet2%	5hmC %	Remarks
Patient 9						MNCs with vehicle showed reduced CSCs. Double treatment led to enhanced DNA methylation
Vehicle	.06	.02	.02	0	0
Carboplatin	.34	.29	.01	.06	.06
Carboplatin + Azacitidine	.33	.13	.04	.07	.19
Patient 10						Treatment of triple negative BCCs reduced DNA hydroxylase
Vehicle	.48	.04	.03	.03	.39
Carboplatin	.2	.04	.06	.02	.06
Carboplatin + Azacitidine	.45	.15	.04	.05	.06

Table showed the results of Patients 9 and 10, untreated and treated with the shown drugs. Mononuclear cells (MNCs) were treated with carboplatin and/or azacitidine. At day 7, the cells were analyzed by phenotype with the two panel antibodies described in Table 2